I just bought this pharma stock for its next generation of blockbuster drugs — and its dividend
Business
Archived
•
October 27, 2026
•
32 views
AbbVie is entering a new chapter of growth, fueled by its blockbuster immunology drugs and expanding neuroscience business. Investor Kevin Simpson shares why he's optimistic.
Source: CNBC Top | https://search.cnbc.com/rs/search/combinedcms/view.xml?partnerId=wrss01&id=100003114 - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!


